O	0	3	The	The	DT	B-NP
O	4	8	role	role	NN	I-NP
O	9	11	of	of	IN	B-PP
O	12	21	syndecans	syndecan	NNS	B-NP
O	22	24	in	in	IN	B-PP
O	25	32	disease	disease	NN	B-NP
O	33	36	and	and	CC	O
B-Pathological_formation	37	42	wound	wound	NN	B-NP
O	43	50	healing	healing	NN	I-NP
O	50	51	.	.	.	O

O	52	61	Syndecans	Syndecan	NNS	B-NP
O	62	65	are	be	VBP	B-VP
O	66	67	a	a	DT	B-NP
O	68	74	family	family	NN	I-NP
O	75	77	of	of	IN	B-PP
B-Cellular_component	78	91	transmembrane	transmembrane	NN	B-NP
O	92	99	heparan	heparan	NN	I-NP
O	100	107	sulfate	sulfate	NN	I-NP
O	108	121	proteoglycans	proteoglycan	NNS	I-NP
O	122	128	widely	widely	RB	B-VP
O	129	138	expressed	express	VBN	I-VP
O	139	141	in	in	IN	B-PP
O	142	146	both	both	CC	O
B-Tissue	147	157	developing	develop	VBG	B-VP
O	158	161	and	and	CC	O
B-Tissue	162	167	adult	adult	JJ	B-NP
I-Tissue	168	175	tissues	tissue	NNS	I-NP
O	175	176	.	.	.	O

O	177	182	Until	Until	IN	B-PP
O	183	191	recently	recently	RB	B-ADVP
O	191	192	,	,	,	O
O	193	198	their	their	PRP$	B-NP
O	199	203	role	role	NN	I-NP
O	204	206	in	in	IN	B-PP
O	207	219	pathogenesis	pathogenesis	NN	B-NP
O	220	223	was	be	VBD	B-VP
O	224	231	largely	largely	RB	B-ADJP
O	232	242	unexplored	unexplored	JJ	I-ADJP
O	242	243	.	.	.	O

O	244	246	In	In	IN	B-PP
O	247	251	this	this	DT	B-NP
O	252	258	review	review	NN	I-NP
O	258	259	,	,	,	O
O	260	262	we	we	PRP	B-NP
O	263	270	discuss	discuss	VBP	B-VP
O	271	274	the	the	DT	B-NP
O	275	283	reported	report	VBN	I-NP
O	284	295	involvement	involvement	NN	I-NP
O	296	298	of	of	IN	B-PP
O	299	308	syndecans	syndecan	NNS	B-NP
O	309	311	in	in	IN	B-PP
O	312	317	human	human	JJ	B-NP
B-Cancer	318	325	cancers	cancer	NNS	I-NP
O	325	326	,	,	,	O
O	327	337	infectious	infectious	JJ	B-NP
O	338	346	diseases	disease	NNS	I-NP
O	346	347	,	,	,	O
O	348	355	obesity	obesity	NN	B-NP
O	355	356	,	,	,	O
B-Pathological_formation	357	362	wound	wound	NN	B-NP
O	363	370	healing	healing	NN	I-NP
O	371	374	and	and	CC	I-NP
O	375	387	angiogenesis	angiogenesis	NN	I-NP
O	387	388	.	.	.	O

O	389	391	In	In	IN	B-PP
O	392	396	some	some	DT	B-NP
B-Cancer	397	404	cancers	cancer	NNS	I-NP
O	404	405	,	,	,	O
O	406	414	syndecan	syndecan	NN	B-NP
O	415	425	expression	expression	NN	I-NP
O	426	429	has	have	VBZ	B-VP
O	430	434	been	be	VBN	I-VP
O	435	440	shown	show	VBN	I-VP
O	441	443	to	to	TO	I-VP
O	444	452	regulate	regulate	VB	I-VP
B-Cell	453	458	tumor	tumor	NN	B-NP
I-Cell	459	463	cell	cell	NN	I-NP
O	464	472	function	function	NN	I-NP
O	473	474	(	(	(	O
O	474	475	e	e	NN	B-NP
O	475	476	.	.	.	O
O	476	477	g	g	NN	B-NP
O	477	478	.	.	.	O
O	479	492	proliferation	proliferation	NN	B-NP
O	492	493	,	,	,	O
O	494	502	adhesion	adhesion	NN	B-NP
O	502	503	,	,	,	O
O	504	507	and	and	CC	O
O	508	516	motility	motility	NN	B-NP
O	516	517	)	)	)	O
O	518	521	and	and	CC	O
O	522	527	serve	serve	VBP	B-VP
O	528	530	as	as	IN	B-PP
O	531	532	a	a	DT	B-NP
O	533	543	prognostic	prognostic	JJ	I-NP
O	544	550	marker	marker	NN	I-NP
O	551	554	for	for	IN	B-PP
B-Cancer	555	560	tumor	tumor	NN	B-NP
O	561	572	progression	progression	NN	I-NP
O	573	576	and	and	CC	O
O	577	584	patient	patient	NN	B-NP
O	585	593	survival	survival	NN	I-NP
O	593	594	.	.	.	O

O	595	598	The	The	DT	B-NP
O	599	610	ectodomains	ectodomain	NNS	I-NP
O	611	614	and	and	CC	I-NP
O	615	622	heparan	heparan	NN	I-NP
O	623	630	sulfate	sulfate	NN	I-NP
O	631	648	glycosaminoglycan	glycosaminoglycan	NN	I-NP
O	649	655	chains	chain	NNS	I-NP
O	656	658	of	of	IN	B-PP
O	659	668	syndecans	syndecan	NNS	B-NP
O	669	672	can	can	MD	B-VP
O	673	677	also	also	RB	I-VP
O	678	681	act	act	VB	I-VP
O	682	684	as	as	IN	B-PP
O	685	694	receptors	receptor	NNS	B-NP
O	694	695	/	/	SYM	B-VP
O	695	697	co	co	AFX	B-NP
O	697	698	-	-	HYPH	I-NP
O	698	707	receptors	receptor	NNS	B-NP
O	708	711	for	for	IN	B-PP
O	712	716	some	some	DT	B-NP
O	717	726	bacterial	bacterial	JJ	I-NP
O	727	730	and	and	CC	I-NP
O	731	736	viral	viral	JJ	I-NP
O	737	746	pathogens	pathogen	NNS	I-NP
O	746	747	,	,	,	O
O	748	757	mediating	mediate	VBG	B-VP
O	758	767	infection	infection	NN	B-NP
O	767	768	.	.	.	O

O	769	771	In	In	IN	B-PP
O	772	780	addition	addition	NN	B-NP
O	780	781	,	,	,	O
O	782	791	syndecans	syndecan	NNS	B-NP
O	792	796	bind	bind	VBP	B-VP
O	797	799	to	to	TO	B-PP
O	800	807	obesity	obesity	NN	B-NP
O	807	808	-	-	HYPH	I-NP
O	808	815	related	relate	VBN	B-NP
O	816	823	factors	factor	NNS	I-NP
O	824	827	and	and	CC	O
O	828	836	regulate	regulate	VBP	B-VP
O	837	842	their	their	PRP$	B-NP
O	843	852	signaling	signaling	NN	I-NP
O	852	853	,	,	,	O
O	854	856	in	in	IN	B-PP
O	857	861	turn	turn	NN	B-NP
O	862	872	modulating	modulate	VBG	B-VP
O	873	877	food	food	NN	B-NP
O	878	889	consumption	consumption	NN	I-NP
O	890	893	and	and	CC	O
O	894	900	weight	weight	NN	B-NP
O	901	908	balance	balance	NN	I-NP
O	908	909	.	.	.	O

O	910	912	In	In	FW	B-NP
O	913	917	vivo	vivo	FW	I-NP
O	918	924	animal	animal	NN	I-NP
O	925	931	models	model	NNS	I-NP
O	932	934	of	of	IN	B-PP
B-Tissue	935	941	tissue	tissue	NN	B-NP
O	942	948	injury	injury	NN	I-NP
O	949	952	and	and	CC	O
O	953	955	in	in	FW	B-NP
O	956	961	vitro	vitro	FW	I-NP
O	962	966	data	datum	NNS	I-NP
O	967	971	also	also	RB	B-ADVP
O	972	981	implicate	implicate	VBP	B-VP
O	982	991	syndecans	syndecan	NNS	B-NP
O	992	994	in	in	IN	B-PP
O	995	1004	processes	process	NNS	B-NP
O	1005	1014	necessary	necessary	JJ	B-ADJP
O	1015	1018	for	for	IN	B-PP
B-Pathological_formation	1019	1024	wound	wound	NN	B-NP
O	1025	1032	healing	healing	NN	I-NP
O	1032	1033	,	,	,	O
O	1034	1043	including	include	VBG	B-PP
B-Cell	1044	1054	fibroblast	fibroblast	NN	B-NP
O	1055	1058	and	and	CC	O
B-Cell	1059	1070	endothelial	endothelial	JJ	B-NP
O	1071	1084	proliferation	proliferation	NN	I-NP
O	1084	1085	,	,	,	O
B-Cell	1086	1090	cell	cell	NN	B-NP
O	1091	1099	motility	motility	NN	I-NP
O	1099	1100	,	,	,	O
O	1101	1113	angiogenesis	angiogenesis	NN	B-NP
O	1113	1114	,	,	,	O
O	1115	1118	and	and	CC	O
B-Cellular_component	1119	1132	extracellular	extracellular	JJ	B-NP
I-Cellular_component	1133	1139	matrix	matrix	NN	I-NP
O	1140	1152	organization	organization	NN	I-NP
O	1152	1153	.	.	.	O

O	1154	1159	These	These	DT	B-NP
O	1160	1163	new	new	JJ	I-NP
O	1164	1172	insights	insight	NNS	I-NP
O	1173	1177	into	into	IN	B-PP
O	1178	1181	the	the	DT	B-NP
O	1182	1193	involvement	involvement	NN	I-NP
O	1194	1196	of	of	IN	B-PP
O	1197	1206	syndecans	syndecan	NNS	B-NP
O	1207	1209	in	in	IN	B-PP
O	1210	1217	disease	disease	NN	B-NP
O	1218	1221	and	and	CC	O
B-Tissue	1222	1228	tissue	tissue	NN	B-NP
O	1229	1235	repair	repair	NN	I-NP
O	1236	1243	coupled	couple	VBN	B-VP
O	1244	1248	with	with	IN	B-PP
O	1249	1252	the	the	DT	B-NP
O	1253	1262	emergence	emergence	NN	I-NP
O	1263	1265	of	of	IN	B-PP
O	1266	1274	syndecan	syndecan	NN	B-NP
O	1274	1275	-	-	HYPH	B-NP
O	1275	1283	specific	specific	JJ	I-NP
O	1284	1293	molecular	molecular	JJ	I-NP
O	1294	1299	tools	tool	NNS	I-NP
O	1300	1303	may	may	MD	B-VP
O	1304	1308	lead	lead	VB	I-VP
O	1309	1311	to	to	TO	B-PP
O	1312	1317	novel	novel	JJ	B-NP
O	1318	1327	therapies	therapy	NNS	I-NP
O	1328	1331	for	for	IN	B-PP
O	1332	1333	a	a	DT	B-NP
O	1334	1341	variety	variety	NN	I-NP
O	1342	1344	of	of	IN	B-PP
O	1345	1350	human	human	JJ	B-NP
O	1351	1359	diseases	disease	NNS	I-NP
O	1359	1360	.	.	.	O

